IDEXX Laboratories Forecast, price target & analysts
IDEXX Laboratories Target price 2025 - Analyst rating & recommendation
IDEXX Laboratories Classifications & Recommendation:
IDEXX Laboratories Price Target
| Target Price | $726.24 |
| Price | $641.14 |
| Potential | 13.27% |
| Number of Estimates | 16 |
| 16 Analysts have issued a price target IDEXX Laboratories 2026 . The average IDEXX Laboratories target price is $726.24. This is 13.27% higher than the current stock price. The highest price target is $824.25 28.56% , the lowest is $393.82 38.58% . | |
| A rating was issued by 21 analysts: 14 Analysts recommend IDEXX Laboratories to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the IDEXX Laboratories stock has an average upside potential 2026 of 13.27% . Most analysts recommend the IDEXX Laboratories stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
17 Analysts have issued a sales forecast IDEXX Laboratories 2025 . The average IDEXX Laboratories sales estimate is $4.3b . This is 6.92% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $4.5b 10.78% , the lowest is $4.1b 1.96% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $3.9b | 6.46% |
|---|---|---|
| 2025 | $4.3b | 10.76% |
| 2026 | $4.7b | 8.15% |
| 2027 | $5.1b | 8.63% |
| 2028 | $5.5b | 9.29% |
| 2029 | $6.0b | 8.30% |
| 2030 | $6.8b | 13.54% |
| 2031 | $7.4b | 8.80% |
| 2032 | $8.0b | 8.37% |
13 Analysts have issued an IDEXX Laboratories EBITDA forecast 2025. The average IDEXX Laboratories EBITDA estimate is $1.5b . This is 6.19% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $1.6b 14.66% , the lowest is $1.4b 0.63% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | $1.3b | 4.09% |
|---|---|---|
| 2025 | $1.5b | 17.12% |
| 2026 | $1.6b | 10.14% |
| 2027 | $1.8b | 9.39% |
| 2028 | $2.0b | 12.63% |
| 2029 | $2.2b | 10.06% |
| 2030 | $2.7b | 21.82% |
| 2031 | $3.0b | 10.67% |
| 2032 | $3.3b | 10.11% |
EBITDA Margin
| 2024 | 32.40% | 2.23% |
|---|---|---|
| 2025 | 34.26% | 5.74% |
| 2026 | 34.89% | 1.84% |
| 2027 | 35.13% | 0.69% |
| 2028 | 36.21% | 3.07% |
| 2029 | 36.80% | 1.63% |
| 2030 | 39.48% | 7.28% |
| 2031 | 40.16% | 1.72% |
| 2032 | 40.80% | 1.59% |
18 IDEXX Laboratories Analysts have issued a net profit forecast 2025. The average IDEXX Laboratories net profit estimate is $1.0b . This is 4.53% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $1.1b 9.99% , the lowest is $968m 1.82% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $888m | 5.07% |
|---|---|---|
| 2025 | $1.0b | 16.04% |
| 2026 | $1.2b | 12.23% |
| 2027 | $1.3b | 12.77% |
| 2028 | $1.4b | 10.83% |
| 2029 | $1.6b | 8.39% |
Net Margin
| 2024 | 22.78% | 1.31% |
|---|---|---|
| 2025 | 23.87% | 4.78% |
| 2026 | 24.77% | 3.77% |
| 2027 | 25.71% | 3.79% |
| 2028 | 26.07% | 1.40% |
| 2029 | 26.09% | 0.08% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
18 Analysts have issued a IDEXX Laboratories forecast for earnings per share. The average IDEXX Laboratories EPS is $12.85 . This is 5.67% higher than earnings per share in the financial year 2024. The highest EPS forecast is $13.53 11.27% , the lowest is $12.07 0.74% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $10.67 | 6.06% |
|---|---|---|
| 2025 | $12.85 | 20.43% |
| 2026 | $14.43 | 12.30% |
| 2027 | $16.27 | 12.75% |
| 2028 | $18.03 | 10.82% |
| 2029 | $19.54 | 8.37% |
P/E ratio
| Current | 52.73 | 13.07% |
|---|---|---|
| 2025 | 49.88 | 5.40% |
| 2026 | 44.44 | 10.91% |
| 2027 | 39.41 | 11.32% |
| 2028 | 35.56 | 9.77% |
| 2029 | 32.81 | 7.73% |
Based on analysts' sales estimates for 2025, the IDEXX Laboratories stock is valued at an EV/Sales of 12.10 and an P/S ratio of 11.88 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 12.94 | 24.18% |
|---|---|---|
| 2025 | 12.10 | 6.50% |
| 2026 | 11.19 | 7.54% |
| 2027 | 10.30 | 7.95% |
| 2028 | 9.42 | 8.50% |
| 2029 | 8.70 | 7.66% |
| 2030 | 7.66 | 11.93% |
| 2031 | 7.04 | 8.09% |
| 2032 | 6.50 | 7.73% |
P/S ratio
| Current | 12.70 | 23.67% |
|---|---|---|
| 2025 | 11.88 | 6.47% |
| 2026 | 10.99 | 7.54% |
| 2027 | 10.11 | 7.95% |
| 2028 | 9.25 | 8.50% |
| 2029 | 8.54 | 7.66% |
| 2030 | 7.53 | 11.93% |
| 2031 | 6.92 | 8.09% |
| 2032 | 6.38 | 7.73% |
IDEXX Laboratories...
Current IDEXX Laboratories Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Morgan Stanley |
Overweight
➜
Overweight
|
Unchanged | Aug 15 2025 |
| Piper Sandler |
Neutral
➜
Neutral
|
Unchanged | Aug 11 2025 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Aug 04 2025 |
| Leerink Partners |
Outperform
➜
Outperform
|
Unchanged | Jul 17 2025 |
| Stifel |
Hold
➜
Hold
|
Unchanged | Jul 02 2025 |
| Leerink Partners |
Outperform
➜
Outperform
|
Unchanged | Jun 11 2025 |
| Stifel |
Hold
➜
Hold
|
Unchanged | May 19 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Morgan Stanley:
Overweight
➜
Overweight
|
Aug 15 2025 |
|
Unchanged
Piper Sandler:
Neutral
➜
Neutral
|
Aug 11 2025 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Aug 04 2025 |
|
Unchanged
Leerink Partners:
Outperform
➜
Outperform
|
Jul 17 2025 |
|
Unchanged
Stifel:
Hold
➜
Hold
|
Jul 02 2025 |
|
Unchanged
Leerink Partners:
Outperform
➜
Outperform
|
Jun 11 2025 |
|
Unchanged
Stifel:
Hold
➜
Hold
|
May 19 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
